. Author manuscript; available in PMC: 2020 May 1.

Published in final edited form as: Transpl Int. 2019 Feb 8;32(5):502–515. doi: 10.1111/tri.13395

Table 1:

Patient Characteristics

Patient Characteristics	All N=113	Center A N=28	Center B N=35	Center C N=50	p-value
Age at transplantation mean +/− SE (years)	41.4 +/− 1.5	41.0+/−3.0	43.6+/−2.7	40.2+/−2.2	0.61
Gender Male n (%)	75 (66.4)	18(64.3)	26(74.3)	31(62.0)	0.48
Etiology of ESRD n (%)					0.12
Glomerulonephritis	40(35.4)	14(50.0)	11(31.4)	15(30.0)
Diabetes mellitus	20(17.7)	3(10.7)	9(25.7)	8(16.0)
Hypertension	16(14.2)	1(3.6)	8(22.9)	7(14.0)
Cystic disease	7(6.2)	2(7.1)	1(2.9)	4(8.0)
Congenital	6(5.3)	0(0)	2(5.7)	4(8.0)
Other	21(18.6)	8(29.6)	4(11.4)	9(18.0)
Unknown	3(2.7)	0(0)	0(0)	3(6.0)
Race n (%)					0.02
Caucasian	64(56.6)	22(78.6)	17(48.6)	25(50.0)
African American	29(25.7)	1(3.6)	11(31.4)	17(34.0)
Hispanic	14(12.4)	2(7.1)	5(14.3)	7(14.0)
Asian	3(2.7)	2(7.1)	0(0)	1(2.0)
American Indian	1(0.88)	1(3.6)	0(0)	0(0)
Other	2(1.8)	0(0)	2(5.7)	0(0)
Donor type n (%)					<0.01
Deceased	50(44.3)	4(14.3)	14(40.0)	32(64.0)
Living related	23(20.4)	8(28.6)	6(17.1)	9(18.0)
Living unrelated	40(35.4)	16(57.1)	15(42.9)	9(18.0)
Re-transplant n(%)	19(16.8)	8(28.6)	1(2.9)	10(20.0)	P=0.02
HLA mismatch
Total mismatch
0–2	8(7.1)	4(14.3)	2(5.7)	2(4.0)	P=0.37
3–4	45(39.8)	8(28.6)	16(45.7)	21(42.0)
5–6	27(53.1)	16(57.1)	17(48.5)	27(54.0)
A mismatch
0	7(6.2)	3(10.7)	2(5.7)	2(4.0)	P=0.71
1	56(49.6)	15(53.6)	16(45.7)	25(50.0)
2	50(44.2)	10(35.7)	17(48.8)	23(46.0)
B mismatch
0	6(5.3)	2(7.1)	2(5.7)	2(4.0)	P=0.91
1	33(29.2)	9(32.1)	11(31.4)	13(26.0)
2	75(65.5)	17(60.7)	22(62.8)	35(70.0)
DR mismatch
0	9(8.0)	2(7.1)	3(8.6)	4(8.0)	P=0.26
1	51(45.1)	8(28.5)	16(45.7)	27(54.0)
2	53(46.9)	18(64.3)	16(45.7)	19(38.0)
History of nonadherence^* n (%)	35(31.0)	12(42.9)	6(17.1)	17(34.0)	P=0.07
Any viral infection requiring immunosuppression reduction^*^†	34(30.1)	6(21.4)	17(48.6)	11(22.0)	P=0.02
Polyomavirus^* n(%)	26(23.0)	6(21.4)	11(31.4)	9(18.0)	P=0.34
Induction Immunosuppression
Anti-thymocyte globulin	83(73.5)	17(60.7)	32(91.4)	34(68.0)	P<0.0001
Alemtuzumab	6(5.3)	6(5.3)	0(0)	0(0)
Basiliximab	10(8.9)	5(17.9)	3(8.5)	2(4.0)
Other	14(12.4)	0(0)	0(0)	14(28.0)
Immunosuppression at time of DSA n (%)
Tacrolimus	91(80.5)	25(89.3)	32(91.4)	34(68.0)	P<0.01
Cyclosporine	17(15.0)	1(3.6)	1(2.9)	15(30.0)
Other	5 (4.4)	2(5.7)	2(7.1)	1(2.0)
Mycophenolate mofetil	107(94.7)	28(100.0)	33(94.3)	46(92.0)	P=0.32
Steroids	78(69.0)	22(78.6)	9(25.7)	47(94.0)	P<0.01

prior to the detection of dn DSA

^†

Includes BK virus, Cytomegalovirus, Epstein Barr Virus, Parvovirus, or combination. At center A, all patients had BK virus (n=6). At center B, BK only (n=9) , BK and CMV (n=2), BK and EBV (n=1), CMV and EBV (n=1), CMV and parvovirus (n=1), CMV viremia (n=3). At center C, BK only (n=9) and CMV only (n=2).